Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 2, 2004, Pages 99-106

  Tsukino, Hiromasa ^a   Kuroda, Yoshiki ^a   Nakao, Hiroyuki ^a   Imai, Hirohisa ^a   Inatomi, Hisato ^b   Osada, Yukio ^a   Katoh, Takahiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Munakata Suikoukai General Hospital   (Japan)

Author keywords

CYP1A2; NAT2; Polymorphism; SULT1A1; Urothelial cancer

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A2; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ACETYLATION; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; SMOKING; TUMOR DIFFERENTIATION; UROGENITAL TRACT TUMOR;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; ARYLSULFOTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; SMOKING; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 1542373500     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0512-0     Document Type: Article

References (46)

1. Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF (2002) Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 90:228-239
2. Bartsch H, Caporaso N, Coda M, Kadlubar F, Malaveille C, Skipper P, Talaska G, Tannenbaum SR, Vineis P (1990) Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 82:1826-1831
3. Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P (1993) Black (aircured) and blond (fluecured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 29:1199-1207
4. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692
5. Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, Weinshilboum RM (2001) Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11:57-68
6. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-845
7. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, Broly F (2001) Five novel natural allelic variants - 951A > C, 1042G > A (D348 N), 1156A > T (I386F), 1217G > A (C406Y) and 1291C > T (C431Y) - of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355-356
8. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902
9. Cohen SM, Shirai T, Steineck G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 205:105-115
10. Crofts FG, Sutter TR, Strickland PT (1998) Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 19:1969-1973
11. Gilissen RA, Bamforth KJ, Stavenuiter JF, Coughtrie MW, Meerman JH (1994) Sulfation of aromatic hydroxamic acids and hydroxylamines by multiple forms of human liver sulfotransferases. Carcinogenesis 15:39-45
12. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376:61-70
13. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R (2000) N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 83:412-417
14. Guengerich FP (1992) Metabolic activation of carcinogens. Pharmacol Ther 54:17-61
15. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, Ovenbeck R (1985) Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 11:263-266
16. Inatomi H, Katoh T, Kawamoto T, Matsumoto T (1999) NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6:446-454
17. Japanese Urological Association and Japanese Society of Pathology (2001) General rules for clinical and pathological studies on bladder cancer. 3rd edn. Kanehara, Tokyo
18. Johns LE, Houlston RS (2000) N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 36: 221-227
19. Kaderlik KR, Kadlubar FF (1995) Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics 5:S108-S117
20. Kadlubar FF (1994) Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 26:37-46
21. Kadlubar FF, Miller JA, Miller EC (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37:805-814
22. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA (1998) A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19:1803-1807
23. Katoh T, Inatomi H, Yang M, Kawamoto T, Matsumoto T, Bell DA (1999) Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 9:401-404
24. Kloth MT, Gee RL, Messing EM, Swaminathan S (1994) Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis 15:2781-2787
25. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ, Lee SH (1994) CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 9:482-489
26. Lewis AJ, Walle UK, King RS, Kadlubar FF, Falany CN, Walle T (1998) Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis 19:2049-2053
27. Marcus PM, Vineis P, Rothman N (2000a) NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10:115-122
28. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N (2000b) Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series metaanalysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 9:461-467
29. Mommsen S, Aagaard J (1986) Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett 32:199-205
30. Morales A, Eidinger D, Bruce AW (2002) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol 167:891-893
31. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808
32. Ozawa S, Tang YM, Yamazoe Y, Kato R, Lang NP, Kadlubar FF (1998) Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 109:237-248
33. Ozawa S, Shimizu M, Katoh T, Miyajima A, Ohno Y, Matsumoto Y, Fukuoka M, Tang YM, Lang NP, Kadlubar FF (1999) Sulfating-activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ((213)Arg) and ST1A3*2 ((213)His), both of which exist in Japanese as well as Caucasians. J Biochem 126:271-277
34. Ozawa S, Katoh T, Inatomi H, Imai H, Kuroda Y, Ichiba M, Ohno Y (2002) Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer 102:418-421
35. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304
36. Raftogianis RB, Wood TC, Weinshilboum RM (1999) Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 58:605-616
37. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
38. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K (2000) Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60:6859-6863
39. Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6:1-30
40. Sobin LH, Wittekind Ch (1997) UICC TNM Classification of malignant tumors. 5th edn. Wiley, New York
41. Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, Sithisarankul P, Strickland P (1996) DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65:314-316
42. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, Golka K, Okkels H, Risch A, Rothman N, Sim E, Taioli E (2001) Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 10:1249-1252
43. Wang Y, Spitz, M R, Tsou AM, Zhang K, Makan N, Wu X (2002) Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 35:137-142
44. Williams JA, Stone EM, Millar BC, Gusterson BA, Grover PL, Phillips DH (1998) Determination of the enzymes responsible for activation of the heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline in the human breast. Pharmacogenetics 8:519-528
45. Yamazoe Y, Nagata K, Yoshinari K, Fujita K, Shiraga T, Iwasaki K (1999) Sulfotransferase catalyzing sulfation of heterocyclic amines. Cancer Lett 143:103-107
46. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR (2001) Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:89-94